1832 Asset Management
MRNA icon

1832 Asset Management’s Moderna MRNA Stock Holding History

1832 Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25
Closed -$2.97K – 816
2024
Q2 		$2.97K Buy
+25
New +$3.16K ﹤0.01% 830
2023
Q4 		– Sell
-10,913
Closed -$1.13M – 886
2023
Q3 		$1.13M Sell
10,913
-5,244
-32% -$585K ﹤0.01% 560
2023
Q2 		$1.96M Buy
16,157
+528
+3% +$70.4K ﹤0.01% 493
2023
Q1 		$2.4M Buy
15,629
+15,614
+104,093% +$2.58M ﹤0.01% 484
2022
Q4 		$2.69K Hold
15
– – ﹤0.01% 857
2022
Q3 		$2K Sell
15
-27,500
-100% -$4.17M ﹤0.01% 859
2022
Q2 		$3.93M Buy
27,515
+27,500
+183,333% +$3.93M 0.01% 442
2022
Q1 		$3K Buy
+15
New +$2.52K ﹤0.01% 908
2021
Q4 		– Sell
-2,426
Closed -$925K – 812
2021
Q3 		$925K Buy
+2,426
New +$895K ﹤0.01% 496

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

1832 Asset Management's MRNA Position: Q3 2024 in Review

1832 Asset Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 25 shares — an estimated $2.97K sold.

1832 Asset Management first reported a position in MRNA in Q3 2021 and held it in 9 quarters. The position peaked at $3.93M in Q2 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • 1832 Asset Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • 1832 Asset Management sold 25 Moderna shares in Q3 2024, an estimated $2.97K.
  • 1832 Asset Management first reported a position in Moderna in Q3 2021 and held it in 9 quarters.
  • 1832 Asset Management's Moderna position peaked at $3.93M in Q2 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on 1832 Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.